The Transcend Plus update for EPIQ CVx and Affiniti CVx systems includes new FDA-cleared AI applications and image quality enhancements designed to improve diagnostic confidence and streamline clinical workflows.
Royal Philips has announced the release of Transcend Plus, an update for its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. The new platform introduces advancements in image quality and a suite of newly US Food and Drug Administration (FDA)-cleared artificial intelligence applications (AI) intended to help cardiology departments manage increasing patient volumes and clinical complexity.
The update is designed to improve sharpness, contrast, and detail in both 2D and 3D imaging, providing clearer visualization of cardiac anatomy and function. According to the company, these enhancements aim to support diagnostic confidence in technically challenging cases. The platform now includes 26 FDA-cleared cardiovascular ultrasound AI applications, such as the new 2D Auto EF and 2D Auto EF Advanced features, which automate measurements to provide fast and reproducible results.
“Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey,” says David Handler, business leader for Cardiology Ultrasound at Philips, in a release.
Automated Tools Support Cardiac Assessment
A key application for the new platform is the assessment of left ventricular (LV) function, which is critical for diagnosing and managing numerous cardiac conditions. The automated tools are intended to reduce operator variability and provide more standardized measurements, particularly in high-volume clinical settings.
The platform supports both contrast and non-contrast imaging. The 2D Auto EF feature allows for assessments when contrast agents are not viable, while the 2D Auto EF Advanced adds AI-powered quantification for both study types, enhancing measurement reliability for patients with poor image quality.
“Artificial intelligence is a tool, not a threat, and I always maintain that human plus AI is going to be better than human alone or AI alone—the 3D Auto CFQ and 3D Auto TV AI applications are examples of this, taking manual, time-consuming processes and automating these measurements in a fast, easy and reproducible way,” says Akhil Narang, MD, director of the Echocardiography Laboratory and associate professor of medicine at the Feinberg School of Medicine, Northwestern University, in a release.
Philips will demonstrate the Transcend Plus platform at the European Society of Cardiology 2025 Congress in Madrid and the American Society of Echocardiography annual meeting in Nashville.
Photo credit: Royal Philips
